Drug General Information
Drug ID	D07URD
Former ID	DIB004804
Drug Name	PRX-102
Synonyms	Galactosidase enzyme replacement therapy (Fabry disease), Protalix
Indication	Fabry's disease [ICD9: 272.7; ICD10:E75.2]		Phase 1/2	[524520]
Company	Protalix biotherapeutics
Structure		Download 2D MOL
Target and Pathway
Target(s)	Alpha-galactosidase A	Target Info	Modulator	[532932]
KEGG Pathway	Galactose metabolism
	Glycerolipid metabolism
	Sphingolipid metabolism
	Glycosphingolipid biosynthesis - globo series
	Lysosome
PathWhiz Pathway	Sphingolipid Metabolism
	Galactose Metabolism
Reactome	Glycosphingolipid metabolism
WikiPathways	Sphingolipid metabolism
References
Ref 524520	ClinicalTrials.gov (NCT01981720) Extension Study of PRX-102 for 24 Months. U.S. National Institutes of Health.
Ref 532932	Characterization of a chemically modified plant cell culture expressed human alpha-Galactosidase-A enzyme for treatment of Fabry disease. Mol Genet Metab. 2015 Feb;114(2):259-67.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.